Creative Planning decreased its holdings in Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 8.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 186,191 shares of the biopharmaceutical company’s stock after selling 16,297 shares during the quarter. Creative Planning owned 0.27% of Portola Pharmaceuticals worth $4,994,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in the company. Oppenheimer & Co. Inc. lifted its holdings in shares of Portola Pharmaceuticals by 1.7% in the third quarter. Oppenheimer & Co. Inc. now owns 22,916 shares of the biopharmaceutical company’s stock valued at $614,000 after buying an additional 393 shares during the period. Cornerstone Advisors Inc. lifted its holdings in shares of Portola Pharmaceuticals by 34.6% in the third quarter. Cornerstone Advisors Inc. now owns 1,801 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 463 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Portola Pharmaceuticals by 12.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,695 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 533 shares during the period. Advisor Group Inc. lifted its holdings in shares of Portola Pharmaceuticals by 7.9% in the second quarter. Advisor Group Inc. now owns 9,302 shares of the biopharmaceutical company’s stock valued at $252,000 after buying an additional 681 shares during the period. Finally, Empire Life Investments Inc. lifted its holdings in shares of Portola Pharmaceuticals by 1.6% in the second quarter. Empire Life Investments Inc. now owns 59,159 shares of the biopharmaceutical company’s stock valued at $1,604,000 after buying an additional 940 shares during the period.
Portola Pharmaceuticals stock traded down $0.43 during mid-day trading on Friday, hitting $27.95. The company’s stock had a trading volume of 26,137 shares, compared to its average volume of 579,651. The firm’s 50 day moving average is $28.23 and its 200 day moving average is $28.77. The company has a market cap of $2.08 billion, a PE ratio of -5.58 and a beta of 2.08. The company has a debt-to-equity ratio of 453.47, a current ratio of 3.63 and a quick ratio of 3.61. Portola Pharmaceuticals Inc has a 52-week low of $14.81 and a 52-week high of $37.95.
Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.14. The firm had revenue of $36.80 million during the quarter, compared to the consensus estimate of $34.64 million. Portola Pharmaceuticals had a negative return on equity of 529.08% and a negative net margin of 275.13%. The business’s revenue for the quarter was up 159.2% on a year-over-year basis. During the same period in the prior year, the business earned ($1.08) EPS. As a group, analysts forecast that Portola Pharmaceuticals Inc will post -3.77 EPS for the current year.
In related news, Director Hollings Renton sold 5,000 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the completion of the sale, the director now directly owns 18,194 shares of the company’s stock, valued at approximately $545,820. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.50% of the stock is currently owned by corporate insiders.
Several brokerages have recently commented on PTLA. Credit Suisse Group reaffirmed a “neutral” rating and set a $35.00 target price on shares of Portola Pharmaceuticals in a report on Monday, August 5th. Morgan Stanley began coverage on Portola Pharmaceuticals in a report on Thursday, September 5th. They set a “hold” rating and a $37.00 target price for the company. BidaskClub raised Portola Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, October 24th. Citigroup reduced their target price on Portola Pharmaceuticals from $51.00 to $44.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. Finally, Cowen reaffirmed a “buy” rating and set a $45.00 target price on shares of Portola Pharmaceuticals in a report on Tuesday. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $38.75.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Recommended Story: Resistance Level
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.